HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA OTC ocular allergy indication guidelines requested by Alcon representative.

This article was originally published in The Tan Sheet

Executive Summary

FDA OTC OCULAR ALLERGY INDICATION GUIDELINES REQUESTED by Harvard Medical School clinical associate professor for ophthalmology Mark Abelson, MD, at the Dec. 9 meeting of the FDA Ophthalmics Subcommittee. Abelson spoke on behalf of Alcon Labs, which markets Naphcon-A OTC eye drops. Abelson's presentation addressed the current situation that some OTC oral antihistamines and ocular vasoconstrictors carry the ocular allergy claim and other OTC antihistamine vasoconstrictor products, like Naphcon-A, do not.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS084597

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel